Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
Hs Koops(University of Groningen), Ferdy J. Lejeune, Franco Di Filippo, John F. Thompson(Melanoma Institute Australia), J. Göhl(University of Groningen), Alexander M.M. Eggermont(University Medical Center Utrecht), Stefan Suciu(St James's University Hospital), Edward T. Krementz, B.B.R. Kroon, D. J. Ruiter(Radboud University Nijmegen), Maurizio Vaglini(University of Groningen)
Cited by 246
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k